The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Mendoza, Argentina
Mendoza, Argentina
Rosario, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Córdoba, Argentina
La Plata, Argentina
Mendoza, Argentina